- BetterLife Pharma (BETR) has closed its marketed public offering
- The company realized gross proceeds of $2,610,000
- Net proceeds will be used for working capital and general corporate purposes
- BetterLife has granted an over-allotment option to increase the size of the offering by up to 15 per cent
- BetterLife Pharma Inc. is an emerging biotechnology company
- BetterLife Pharma Inc. (BETR) is up 3.33 per cent, trading at C$0.31 per share at 11 am ET
BetterLife Pharma (BETR) has closed its marketed public offering.
The company issued 6,525,000 units at a price of $0.40 per unit for gross proceeds of $2,610,000.
Each unit consists of one common share and one share purchase warrant. Each warrant entitles the holder to purchase one share at an exercise price of $0.50 expiring on May 28, 2024.
The net proceeds will be used for working capital and general corporate purposes.
The offering was led by Research Capital Corporation as sole agent and sole bookrunner.
BetterLife has granted an over-allotment option to increase the size of the offering by up to an additional 15 per cent exercisable at any time up to 30 days following the closing of the offering.
BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies.
BetterLife Pharma Inc. (BETR) is up 3.33 per cent, trading at C$0.31 per share at 11 am ET.
